Expression and prognostic analysis of Rho GTPase-activating protein 11A in lung adenocarcinoma

Expression and prognostic analysis of Rho GTPase-activating protein 11A in lung adenocarcinoma

Rho GTPase-activating protein 11A (ARHGAP11A) is a member of the Rho GTPase-activating protein (RhoGAP) subfamily. However, its expression, prognostic significance and clinicopathologic factors correlation in lung adenocarcinoma is still unclear. The original gene expression profile, survival data,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of translational medicine 2021-05, Vol.9 (10), p.872-872
Hauptverfasser: Chen, Shuchen, Duan, He, Xie, Yusai, Li, Xiaoling, Zhao, Yuxia
Format: Artikel
Sprache:eng
Schlagworte:
Original
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 872
container_issue 10
container_start_page 872
container_title Annals of translational medicine
container_volume 9
creator Chen, Shuchen
Duan, He
Xie, Yusai
Li, Xiaoling
Zhao, Yuxia
description Rho GTPase-activating protein 11A (ARHGAP11A) is a member of the Rho GTPase-activating protein (RhoGAP) subfamily. However, its expression, prognostic significance and clinicopathologic factors correlation in lung adenocarcinoma is still unclear. The original gene expression profile, survival data, and clinical information of patients with lung adenocarcinoma (LUAD) were downloaded from The Cancer Genome Atlas (TCGA) database. The expression difference of ARHGAP11A between LUAD tissues and adjacent normal tissues in the TCGA database was analyzed by using R software, and verified by the Oncomine database and immunohistochemical (IHC) assay of LUAD sections. Logistic regression was applied to analyze the relationship between the expression of ARHGAP11A and clinicopathological factors of LUAD. Kaplan-Meier (KM) survival curves and a Cox proportional-hazards model were selected to evaluate the prognostic significance of ARHGAP11A expression. Gene set enrichment analysis (GSEA) software was applied to screen the tumor signaling pathways associated with the low and high expression group of ARHGAP11A in LUAD. The TCGA database showed that the expression of ARHGAP11A was significantly higher in LUAD tissues than in normal tissues (P
doi_str_mv 10.21037/atm-21-2113
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8184474</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2544877114</sourcerecordid><originalsourceid>FETCH-LOGICAL-c314t-4bd8cb79d1e23e7fcdd36940c25dc2fd6961325aeaafe5a9457fec137832d85a3</originalsourceid><addsrcrecordid>eNpVkctLAzEQxoMoWqo3z7JHD65m8tjHRZDiCwRF6tUwTbI1spvUZCv637u1WhQG5vXjm4GPkEOgpwwoL8-w73IGQwDfIiPGqcxlxevtP_UeOUjplVIKDGpO6S7Z4wIKIWkxIs-XH4toU3LBZ-hNtohh7kPqnR5abD-TS1losseXkF1PHzDZHHXv3rF3fr6Ce-t8BnCRDaldDjM01geNUTsfOtwnOw22yR785DF5urqcTm7yu_vr28nFXa45iD4XM1PpWVkbsIzbstHG8KIWVDNpNGtMURfAmUSL2FiJtZBlYzXwsuLMVBL5mJyvdRfLWWeNtr6P2KpFdB3GTxXQqf8b717UPLyrCiohSjEIHP8IxPC2tKlXnUvati16G5ZJMSlEVZYAK_RkjeoYUoq22ZwBqr5dUYMrQ6VWrgz40d_XNvCvB_wLM1aKSw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2544877114</pqid></control><display><type>article</type><title>Expression and prognostic analysis of Rho GTPase-activating protein 11A in lung adenocarcinoma</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Chen, Shuchen ; Duan, He ; Xie, Yusai ; Li, Xiaoling ; Zhao, Yuxia</creator><creatorcontrib>Chen, Shuchen ; Duan, He ; Xie, Yusai ; Li, Xiaoling ; Zhao, Yuxia</creatorcontrib><description>Rho GTPase-activating protein 11A (ARHGAP11A) is a member of the Rho GTPase-activating protein (RhoGAP) subfamily. However, its expression, prognostic significance and clinicopathologic factors correlation in lung adenocarcinoma is still unclear. The original gene expression profile, survival data, and clinical information of patients with lung adenocarcinoma (LUAD) were downloaded from The Cancer Genome Atlas (TCGA) database. The expression difference of ARHGAP11A between LUAD tissues and adjacent normal tissues in the TCGA database was analyzed by using R software, and verified by the Oncomine database and immunohistochemical (IHC) assay of LUAD sections. Logistic regression was applied to analyze the relationship between the expression of ARHGAP11A and clinicopathological factors of LUAD. Kaplan-Meier (KM) survival curves and a Cox proportional-hazards model were selected to evaluate the prognostic significance of ARHGAP11A expression. Gene set enrichment analysis (GSEA) software was applied to screen the tumor signaling pathways associated with the low and high expression group of ARHGAP11A in LUAD. The TCGA database showed that the expression of ARHGAP11A was significantly higher in LUAD tissues than in normal tissues (P&lt;0.001). The up-regulation of ARHGAP11A in LUAD was verified by the Oncomine database (P&lt;0.001) and IHC assay (P&lt;0.001). Logistic regression analysis revealed the high expression of ARHGAP11A to be closely related to age, sex, advanced pathological stage, advanced T stage, and lymph node metastasis. The KM plots based on the TCGA and KM plotter databases indicated that patients with LUAD highly expressing ARHGAP11A had a poorer overall survival (OS) than patients with low expression of ARHGAP11A. Multivariate Cox regression analysis showed that the high expression of ARHGAP11A could be an important independent predictor of a poor prognosis of LUAD [hazards ratio (HR) =1.385; P&lt;0.001]. GSEA indicated that 10 signal pathways were significantly enriched in LUAD samples with the ARHGAP11A expression phenotype. ARHGAP11A may play a carcinogenic role in the malignant progression of LUAD, and it can be considered as a new independent prognostic factor and potential therapeutic target for LUAD.</description><identifier>ISSN: 2305-5839</identifier><identifier>EISSN: 2305-5839</identifier><identifier>DOI: 10.21037/atm-21-2113</identifier><identifier>PMID: 34164506</identifier><language>eng</language><publisher>China: AME Publishing Company</publisher><subject>Original</subject><ispartof>Annals of translational medicine, 2021-05, Vol.9 (10), p.872-872</ispartof><rights>2021 Annals of Translational Medicine. All rights reserved.</rights><rights>2021 Annals of Translational Medicine. All rights reserved. 2021 Annals of Translational Medicine.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c314t-4bd8cb79d1e23e7fcdd36940c25dc2fd6961325aeaafe5a9457fec137832d85a3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184474/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184474/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34164506$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Shuchen</creatorcontrib><creatorcontrib>Duan, He</creatorcontrib><creatorcontrib>Xie, Yusai</creatorcontrib><creatorcontrib>Li, Xiaoling</creatorcontrib><creatorcontrib>Zhao, Yuxia</creatorcontrib><title>Expression and prognostic analysis of Rho GTPase-activating protein 11A in lung adenocarcinoma</title><title>Annals of translational medicine</title><addtitle>Ann Transl Med</addtitle><description>Rho GTPase-activating protein 11A (ARHGAP11A) is a member of the Rho GTPase-activating protein (RhoGAP) subfamily. However, its expression, prognostic significance and clinicopathologic factors correlation in lung adenocarcinoma is still unclear. The original gene expression profile, survival data, and clinical information of patients with lung adenocarcinoma (LUAD) were downloaded from The Cancer Genome Atlas (TCGA) database. The expression difference of ARHGAP11A between LUAD tissues and adjacent normal tissues in the TCGA database was analyzed by using R software, and verified by the Oncomine database and immunohistochemical (IHC) assay of LUAD sections. Logistic regression was applied to analyze the relationship between the expression of ARHGAP11A and clinicopathological factors of LUAD. Kaplan-Meier (KM) survival curves and a Cox proportional-hazards model were selected to evaluate the prognostic significance of ARHGAP11A expression. Gene set enrichment analysis (GSEA) software was applied to screen the tumor signaling pathways associated with the low and high expression group of ARHGAP11A in LUAD. The TCGA database showed that the expression of ARHGAP11A was significantly higher in LUAD tissues than in normal tissues (P&lt;0.001). The up-regulation of ARHGAP11A in LUAD was verified by the Oncomine database (P&lt;0.001) and IHC assay (P&lt;0.001). Logistic regression analysis revealed the high expression of ARHGAP11A to be closely related to age, sex, advanced pathological stage, advanced T stage, and lymph node metastasis. The KM plots based on the TCGA and KM plotter databases indicated that patients with LUAD highly expressing ARHGAP11A had a poorer overall survival (OS) than patients with low expression of ARHGAP11A. Multivariate Cox regression analysis showed that the high expression of ARHGAP11A could be an important independent predictor of a poor prognosis of LUAD [hazards ratio (HR) =1.385; P&lt;0.001]. GSEA indicated that 10 signal pathways were significantly enriched in LUAD samples with the ARHGAP11A expression phenotype. ARHGAP11A may play a carcinogenic role in the malignant progression of LUAD, and it can be considered as a new independent prognostic factor and potential therapeutic target for LUAD.</description><subject>Original</subject><issn>2305-5839</issn><issn>2305-5839</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpVkctLAzEQxoMoWqo3z7JHD65m8tjHRZDiCwRF6tUwTbI1spvUZCv637u1WhQG5vXjm4GPkEOgpwwoL8-w73IGQwDfIiPGqcxlxevtP_UeOUjplVIKDGpO6S7Z4wIKIWkxIs-XH4toU3LBZ-hNtohh7kPqnR5abD-TS1losseXkF1PHzDZHHXv3rF3fr6Ce-t8BnCRDaldDjM01geNUTsfOtwnOw22yR785DF5urqcTm7yu_vr28nFXa45iD4XM1PpWVkbsIzbstHG8KIWVDNpNGtMURfAmUSL2FiJtZBlYzXwsuLMVBL5mJyvdRfLWWeNtr6P2KpFdB3GTxXQqf8b717UPLyrCiohSjEIHP8IxPC2tKlXnUvati16G5ZJMSlEVZYAK_RkjeoYUoq22ZwBqr5dUYMrQ6VWrgz40d_XNvCvB_wLM1aKSw</recordid><startdate>202105</startdate><enddate>202105</enddate><creator>Chen, Shuchen</creator><creator>Duan, He</creator><creator>Xie, Yusai</creator><creator>Li, Xiaoling</creator><creator>Zhao, Yuxia</creator><general>AME Publishing Company</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>202105</creationdate><title>Expression and prognostic analysis of Rho GTPase-activating protein 11A in lung adenocarcinoma</title><author>Chen, Shuchen ; Duan, He ; Xie, Yusai ; Li, Xiaoling ; Zhao, Yuxia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c314t-4bd8cb79d1e23e7fcdd36940c25dc2fd6961325aeaafe5a9457fec137832d85a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Original</topic><toplevel>online_resources</toplevel><creatorcontrib>Chen, Shuchen</creatorcontrib><creatorcontrib>Duan, He</creatorcontrib><creatorcontrib>Xie, Yusai</creatorcontrib><creatorcontrib>Li, Xiaoling</creatorcontrib><creatorcontrib>Zhao, Yuxia</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Annals of translational medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Shuchen</au><au>Duan, He</au><au>Xie, Yusai</au><au>Li, Xiaoling</au><au>Zhao, Yuxia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Expression and prognostic analysis of Rho GTPase-activating protein 11A in lung adenocarcinoma</atitle><jtitle>Annals of translational medicine</jtitle><addtitle>Ann Transl Med</addtitle><date>2021-05</date><risdate>2021</risdate><volume>9</volume><issue>10</issue><spage>872</spage><epage>872</epage><pages>872-872</pages><issn>2305-5839</issn><eissn>2305-5839</eissn><abstract>Rho GTPase-activating protein 11A (ARHGAP11A) is a member of the Rho GTPase-activating protein (RhoGAP) subfamily. However, its expression, prognostic significance and clinicopathologic factors correlation in lung adenocarcinoma is still unclear. The original gene expression profile, survival data, and clinical information of patients with lung adenocarcinoma (LUAD) were downloaded from The Cancer Genome Atlas (TCGA) database. The expression difference of ARHGAP11A between LUAD tissues and adjacent normal tissues in the TCGA database was analyzed by using R software, and verified by the Oncomine database and immunohistochemical (IHC) assay of LUAD sections. Logistic regression was applied to analyze the relationship between the expression of ARHGAP11A and clinicopathological factors of LUAD. Kaplan-Meier (KM) survival curves and a Cox proportional-hazards model were selected to evaluate the prognostic significance of ARHGAP11A expression. Gene set enrichment analysis (GSEA) software was applied to screen the tumor signaling pathways associated with the low and high expression group of ARHGAP11A in LUAD. The TCGA database showed that the expression of ARHGAP11A was significantly higher in LUAD tissues than in normal tissues (P&lt;0.001). The up-regulation of ARHGAP11A in LUAD was verified by the Oncomine database (P&lt;0.001) and IHC assay (P&lt;0.001). Logistic regression analysis revealed the high expression of ARHGAP11A to be closely related to age, sex, advanced pathological stage, advanced T stage, and lymph node metastasis. The KM plots based on the TCGA and KM plotter databases indicated that patients with LUAD highly expressing ARHGAP11A had a poorer overall survival (OS) than patients with low expression of ARHGAP11A. Multivariate Cox regression analysis showed that the high expression of ARHGAP11A could be an important independent predictor of a poor prognosis of LUAD [hazards ratio (HR) =1.385; P&lt;0.001]. GSEA indicated that 10 signal pathways were significantly enriched in LUAD samples with the ARHGAP11A expression phenotype. ARHGAP11A may play a carcinogenic role in the malignant progression of LUAD, and it can be considered as a new independent prognostic factor and potential therapeutic target for LUAD.</abstract><cop>China</cop><pub>AME Publishing Company</pub><pmid>34164506</pmid><doi>10.21037/atm-21-2113</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2305-5839
ispartof Annals of translational medicine, 2021-05, Vol.9 (10), p.872-872
issn 2305-5839
2305-5839
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8184474
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central
subjects Original
title Expression and prognostic analysis of Rho GTPase-activating protein 11A in lung adenocarcinoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T15%3A48%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Expression%20and%20prognostic%20analysis%20of%20Rho%20GTPase-activating%20protein%2011A%20in%20lung%20adenocarcinoma&rft.jtitle=Annals%20of%20translational%20medicine&rft.au=Chen,%20Shuchen&rft.date=2021-05&rft.volume=9&rft.issue=10&rft.spage=872&rft.epage=872&rft.pages=872-872&rft.issn=2305-5839&rft.eissn=2305-5839&rft_id=info:doi/10.21037/atm-21-2113&rft_dat=%3Cproquest_pubme%3E2544877114%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2544877114&rft_id=info:pmid/34164506&rfr_iscdi=true